Adults, median age around 50; wide range including children
Fewer than 1 per million per year
Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.
Clinical Presentation & Hallmark Symptoms
Presenting signs most frequently observed across clinical case series
Genomic Profiling & Defining Molecular Lesions
Critical diagnostic fusions, somatic mutations, and therapeutic targets
Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.
Standard-of-Care Treatment Protocol
Frontline and multimodal strategies established under international consensus guidelines
Surgical resection for localised disease
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Radiotherapy for localised or residual disease
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Multi-agent chemotherapy (lymphoma-style regimens) for disseminated disease
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
MAPK pathway inhibition where BRAF or MAP2K1 alterations are found
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Allogeneic transplant considered in fit patients with responsive disease
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Prognosis & Disease Trajectory
Objective clinical outlook without false reassurance
Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.
Active Research, Biomarkers & Clinical Trials
Novel investigational agents, phase I/II trials, and international rare disease consortia
Molecular profiling for MAPK pathway alterations is now standard practice at expert centres, and MEK/BRAF inhibitors are being used with reported durable responses; CSF1R-directed agents are under study.
Need Help Matching to an Active Rare Cancer Trial?
ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.
Verified Specialists for Histiocytic Sarcoma
Dr. Eli L. Diamond
Neuro-oncologist
MSKCC
New York, USA
Dr. Kevin Tay
Hematologist-Oncologist
OncoCare / NCCS
Singapore, Singapore
Dr. Julien Haroche
Internist
Pitié-Salpêtrière Hospital
Paris, France
Dr. Sameer Rastogi
Sarcoma Medical Oncologist
AIIMS, New Delhi
New Delhi, India
Designated Cancer Centers with Dedicated Programs
NCI-Designated Comprehensive Cancer Center
World-leading rare tumor board & pediatric solid tumor protocols
NCI-Designated Comprehensive Cancer Center
Largest specialized rare cancer and sarcoma multidisciplinary program
NCI-Designated Comprehensive Cancer Center
Pioneering genomic molecular tumor boards & rare histologies
NCI-Designated Comprehensive Cancer Center
High-volume surgical oncology & rare endocrine/neuroendocrine expertise
Frequently Asked Clinical Questions
Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options
Related Rare Malignancies in Catalog
Facing a Diagnosis of Histiocytic Sarcoma?
Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.